osimertinib
astrazeneca
['lcsm,(-blcsm)', 'osimertinib']
3 years later.... os is published now. don't just read the data at face value. a lot of issue with the subsequent tx in the placebo arm, only 23% of the pts got subsequent osimertinib!! big pharma is always one step ahead. #asco #lcsm 
Onkologie PharmD - It's not personal, it's about the data.
Read Malignant and listen to Plenary Session. 
Kaiser Permanente